MYOZYME

Opinions on drugs - Posted on May 21 2013

Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.

Low	The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease.

minor

The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease.

Évaluation des médicaments

My account